Mark D. Pegram, MD

Articles by Mark D. Pegram, MD

Novel Therapy for Relapsed/Refractory HR+ BC: IO Therapy and PARP Inhibition

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

August 15th 2022

Expert perspectives on trial results with both IO and PARP inhibitor therapy, respectively, in the setting of relapsed/refractory HR+/HER2- breast cancer.

Considerations for Use of ADCs in HER2-Low Breast Cancer

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

August 15th 2022

A brief discussion on the use of antibody drug conjugates in patients with relapsed/refractory breast cancer and HER2-low expression.

Recurrence Patterns in Early-Stage HR+ Breast Cancer

ByMark D. Pegram, MD,Lee S. Schwartzberg, MD, FACP

August 12th 2022

Drs Mark Pegram and Lee Schwartzberg examine late recurrence patterns in patients with HR+ breast cancer.

Updated Guidelines for the Management of HR+ Breast Cancer

ByMark D. Pegram, MD,Lee S. Schwartzberg, MD, FACP

August 12th 2022

Experts highlight some important and surprising updates in the ASCO guidelines for the management of HR+ breast cancer.

ADCs in HR+/HER2- Advanced BC: Results From TROPICS-02 and DESTINY-Breast04

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

August 8th 2022

Centering discussion on the TROPICS-02 and DESTINY-Breast04 trials, panelists consider the advent of antibody drug conjugates in relapsed/refractory HR+ breast cancer.

Second-Line Use of CDK4/6 Inhibitors in HR+ Breast Cancer

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

August 8th 2022

Shared insight on the potential role of CDK4/6 inhibitors in the second-line setting of relapsed/refractory HR+/HER2- breast cancer.

Measuring Ki-67 Levels to Inform HR+ Breast Cancer Treatment

ByMark D. Pegram, MD,Lee S. Schwartzberg, MD, FACP

August 5th 2022

Lee Schwartzberg, MD, FACP, explains how Ki-67 is measured and used to inform management strategies for HR+ breast cancer at his clinical practice.

The Evolution of Early-Stage HR+ Breast Cancer Management

ByMark D. Pegram, MD,Lee S. Schwartzberg, MD, FACP

August 5th 2022

Lee Schwartzberg, MD, FACP, and Mark Pegram, MD, discuss how the management of early-stage HR+ breast cancer has changed over time.

Novel Therapy for Relapsed/Refractory HR+ BC: PI3K Inhibitors

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

August 1st 2022

Expert perspectives on the current paradigm of PI3K inhibition in the setting of relapsed/refractory HR+/HER2- breast cancer.

Novel Therapy for Relapsed/Refractory HR+ BC: Oral SERDs

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

August 1st 2022

A brief overview of oral SERDs currently being investigated in the setting of relapsed/refractory HR+/HER2- breast cancer.

HR+ BC: Is There Still a Role for Everolimus Post–Endocrine Therapy?

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

July 25th 2022

Panelists briefly consider the ongoing role of everolimus in relapsed/refractory HR+/HER2- breast cancer given recent shifts in the treatment paradigm.

Novel Treatment Approaches to Relapsed/Refractory HR+ Breast Cancer

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

July 25th 2022

Comprehensive insight on novel treatment approaches in the setting of relapsed/refractory HR+/HER2- breast cancer, including oral SERDs, SERMs, and ER PROTAC degraders.

Is There a Role for CDK4/6 Inhibition in HR+/HER2+ Breast Cancer?

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

July 18th 2022

Shifting their focus to the HR+/HER2+ setting of breast cancer, expert panelists consider the potential of CDK4/6 inhibition in light of clinical trial data.

Frontline Combination Strategies in HR+/HER2- BC

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

July 18th 2022

A brief review of frontline combination strategies in the context of multiple driver pathways in HR+/HER2- breast cancer.

Real-World Use of CDK4/6 Inhibition in HR+/HER2- Breast Cancer

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

July 11th 2022

Experts home in on real-world data and resistance mechanisms to discuss practical use of CDK4/6 inhibition in HR+/HER2- breast cancer.v

HR+/HER2- Breast Cancer: Identifying Barriers to Use of CDK4/6 Inhibition

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

July 11th 2022

Comprehensive insight on the barriers to CDK4/6 inhibition in HR+/HER2- breast cancer, from both medical and accessibility perspectives.

HR+/HER2- BC: Selecting a CDK4/6 Inhibitor in the Frontline Setting

ByHope S. Rugo, MD,Aditya Bardia, MD,Anne P. O’Dea, MD,Komal Jhaveri, MD,Mark D. Pegram, MD

July 4th 2022

Taking into account all 3 available CDK4/6 inhibitors in HR+/HER2- breast cancer, experts consider how they’d select frontline therapy in this setting.

CKD4/6 Inhibition in HR+/HER2- BC: Trial Data With Palbociclib

ByHope S. Rugo, MD,Aditya Bardia, MD,Komal Jhaveri, MD,Mark D. Pegram, MD,Anne P. O’Dea, MD

July 4th 2022

Panelists share insight on clinical trial data behind use of palbociclib in the frontline setting of HR+/HER2- breast cancer.

CKD4/6 Inhibition in HR+/HER2- BC: Trial Data With Abemaciclib and Ribociclib

ByHope S. Rugo, MD,Aditya Bardia, MD,Komal Jhaveri, MD,Mark D. Pegram, MD,Anne P. O’Dea, MD

June 27th 2022

Focusing on the frontline setting of HR+/HER2- breast cancer, panelists discuss clinical trial data with abemaciclib and ribociclib, respectively.

Frontline Treatment Strategies for HR+/HER2- Breast Cancer

ByHope S. Rugo, MD,Aditya Bardia, MD,Komal Jhaveri, MD,Mark D. Pegram, MD,Anne P. O’Dea, MD

June 27th 2022

Expert perspectives on the evolving treatment paradigm for patients receiving frontline therapy for HR+/HER2- breast cancer.

ESMO 2021: Updates in Triple Negative Breast Cancer

ByJoyce A. O'Shaughnessy, MD,Sara M. Tolaney, MD, MPH,Sara A. Hurvitz, MD,Mark D. Pegram, MD

November 15th 2021

Drs Joyce O’Shaughnessy, Sara Tolaney, Sara Hurvitz, and Mark Pegram examine recent trial data from ESMO 2021 on triple-negative breast cancer.

Updates in HR+/HER2- Breast Cancer: The MONALEESA-2 Trial

ByJoyce A. O'Shaughnessy, MD,Sara M. Tolaney, MD, MPH,Sara A. Hurvitz, MD,Mark D. Pegram, MD

November 8th 2021

Breast oncologists explain results from the phase III MONALEESA-2 trial presented at ESMO 2021, and its clinical implications.

Interesting Trials in HER2+ Breast Cancer

ByJoyce O'Shaughnessy, MD,Sara M. Tolaney, MD, MPH,Sara A. Hurvitz, MD,Mark D. Pegram, MD

November 1st 2021

Key opinion leaders review data from the phase III TULIP trial in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer and the ExteNET study on extended adjuvant treatment with neratinib.

Optimizing the Management of ILD: Take-Home Messages

ByMark D. Pegram, MD,Charles Powell, MD,Joyce A. O'Shaughnessy

October 29th 2021

Experts highlight key messages regarding optimal identification and management of interstitial lung disease.

Future Landscape of HER2+ MBC

BySara M. Tolaney, MD, MPH,Mark D. Pegram, MD

October 26th 2021

Drs. Sara Tolaney and Mark Pegram discuss promising therapies and upcoming mechanisms of actions to treat HER2+ metastatic breast cancer.

Other Trials with Trastuzumab Deruxtecan in Breast Cancer

BySara M. Tolaney, MD, MPH,Mark D. Pegram, MD

October 26th 2021

Breast cancer experts, Drs. Sara Tolaney and Mark Pegram discuss ongoing and noteworthy trials with trastuzumab deruxtecan in mBC.

Sequencing in HER2+ MBC

BySara M. Tolaney, MD, MPH,Mark D. Pegram, MD

October 26th 2021

Sara Tolaney, MD, and Mark Pegram, MD, discuss their rationale for sequencing of most effective therapy in treatment of patients with metastatic breast cancer.

Updates in HER2+ Breast Cancer from ESMO 2021

ByJoyce A. O'Shaughnessy,Sara M. Tolaney, MD, MPH,Sara A. Hurvitz, MD,Mark D. Pegram, MD

October 25th 2021

Expert oncologists discuss data from several phase 2 and phase 3 trials presented at ESMO 2021 on the use of trastuzumab deruxtecan for HER2-positive breast cancer and how it impacts their practices.